Recent developments in U.S. cannabis policy have sparked renewed debate across the country after Donald Trump confirmed that his administration was considering a significant change to how marijuana is classified under federal law. The announcement, originally made last summer, indicated that the federal government was reviewing whether cannabis should remain a Schedule I substance—one of the strictest classifications under the Controlled Substances Act, typically reserved for drugs considered to have a high potential for abuse and no accepted medical use. Speaking about the issue at the time, Trump acknowledged the complexity of the topic and suggested a decision could come relatively soon.

“We’re looking at reclassification, and we’ll make a determination over the next few weeks,” he said, emphasizing that the matter involves a complicated balance between medical research, public policy, and law enforcement considerations. If the federal government ultimately decides to reclassify marijuana to Schedule III, it could represent one of the most consequential shifts in U.S. drug policy in decades, potentially affecting medical research, prescription rules, and state-level legalization efforts across the country.